Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The company says the deal will bolster its cancer immunotherapy efforts.

Sanofi Acquiring Immunotherapy Biotech Kiadis in $358 Million Deal

AmerisourceBergen

Arrow Financial

Chubb

Enbridge

Enterprise Products Partners

Essex Property Trust

Johnson & Johnson

Kimberly-Clark

Altria

Northrop Grumman

Philip Morris

AT&T

UMB Financial

The pandemic is out of control all over the world, with daily records in new cases and a mounting death toll. Europe is beginning to lock down again and IHME expects up to 20 US states to follow suit starting in late November.

15 High-Yield/Low Volatility Blue Chips For The Ultimate Crash-Proof Retirement Portfolio

                                                                                                                                                             Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) (the "Decree") in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the "Offer Document") approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the "AFM") and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ''FSMA''). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi offers to acquire Kiadis for €308 million

Sanofi (SNY) CEO Paul Hudson on Q3 2020 Results - Earnings Call Transcript

Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.

Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised

Regeneron Pharmaceuticals

European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)

Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology

Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology

GlaxoSmithKline

Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. The doses will go to the COVAX Facility, a World Health Organization-backed initiative meant to give rich and poor countries alike equal access to crucial COVID-19 vaccines once.

Sanofi, GlaxoSmithKline pledge 200M COVID-19 vaccines for global use

The companies hope to apply for approval in the first half of 2021.

GSK And Sanofi Pledge 200 Million Vaccine Doses To Covid-19 Alliance

Sanofi and GSK's vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials.

Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

AstraZeneca

As we (hopefully) approach the finish line in the COVID-19 vaccine race, it's a wonderful time to buy shares of Novavax and Sanofi.

2 Surefire Coronavirus Stocks to Buy Right Now

Carlisle Companies

4 Blue Chips To Sleep Well At Night In These Uncertain Times

Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.

Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage

Telesis Bio Inc

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.

Sanofi and Translate Bio Have a COVID-19 Vaccine Candidate Ready for Clinical Trials

Translate Bio and Sanofi announced positive preclinical results for their Covid-19 vaccine candidate in mice and non-human primates, and said human testing will start this quarter; TBIO rose. The post Sanofi, Translate Bio Post Positive Early Covid-19 Vaccine Results; Plan Human Testing appeared first on Investor's Business Daily.

Sanofi, Translate Bio Post Positive Early Covid-19 Vaccine Results; Plan Human Testing

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

BioNTech SE

Inovio Pharmaceuticals

Moderna

Novavax

Pfizer

The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.

There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand

Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.

Sanofi's Dupixent Meets All Goals in Asthma Study for Children

CureVac B.V

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data from trial results hint that Dupixent holds a lot of promise for children (aged between six to 11 years) with uncontrolled moderate-to-severe asthma.

Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children

British American Tobacco

Nestle SA

Novo Nordisk

Novartis

Roche Holding AG

SAP SE

Unilever

Vanguard FTSE Developed Markets ETF

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best European stocks are one such store of value-priced diversification.

10 Best European Stocks for an Income-Rich Recovery

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

Here's a switch: Analysts are predicting sales for a Sanofi (NASDAQ:SNY) blockbuster drug that exceeds the company's forecast.

News for Sanofi Stock (SNY)